会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Compounds for reversing drug resistance
    • 用于逆转耐药性的化合物
    • US06297216B1
    • 2001-10-02
    • US08737255
    • 1997-02-19
    • Balazs SarkadiJanos SeprodiOrsolya CsukaMaria MagocsiImre MezoIstvan PalyiIstvan TeplanZsolt VadaszBorbala Vincze
    • Balazs SarkadiJanos SeprodiOrsolya CsukaMaria MagocsiImre MezoIstvan PalyiIstvan TeplanZsolt VadaszBorbala Vincze
    • A61K3804
    • C07K5/06113A61K38/00C07K5/0215C07K5/0606C07K5/06078C07K5/06086C07K5/06104
    • The invention features novel peptide derivatives called Reversins, and provides for their use in a method of reducing the activity of the multi-drug transporter protein MDR1 in order to overcome multidrug resistance in a mammal. The peptide derivatives are of the formula (I) X1n-X2-X3(X4)n-X5, wherein n is 0 or 1, and each n is the same or different; X1 is BOC, BOC-Asu, Z-Asu, benzyloxycarbonyl, Glu(OBzl)-OBzl, Trp-OMe, Trp-Phe-OMe, Phe-Trp-OMe, Phe-Phe-OtBu, Trp-Trp-OtBu, indoloacetyl, benzoyl, an alkylanine of 1-4 carbons, dibenzylamide, tryptamide, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylamide or dicyclohexylamide; X2 is Glu(OBzl), Asp(OBzl), succinyl, O,O-dibenzoyltartaroyl, diphenoyl, muconyl, Thx, Cpa, Asu, Nal, Pen, Phg, Dbt, Lys(BOC), Lys(Z), Cys(Bzl), Thr(Bzl), Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Phe, Tyr(Bzl), or Ser(Bal); X3 is Asp, Asu, Lys, Glu, Trp, Thx, Cpa, Nal, Pen, Phg, Dbt, Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Tyr, Phe, or Tyr(Bzl); X4 is BOC-Glu(OBzl), Glu(OBzl), Asu, OBzl, Bzl, BOC, BOC-Lys(BOC), Z-Glu(OtBu), Asp(OBzl), Asp(OBz)-OBzl, benzyloxycarbonyl, O-(cyclo-hexyl), fluorenylmethyl ester, Glu(OtBu), Glu(OtBu)-OBzl, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylarnide, or dicyclohexylamide; and X5 is OMe, OBzl, OtBu, Phe-OMe, -O-(cyclohexyl), Trp-OMe, (chlorophenyl)-isobutylamide, fluorenylmethyl ester, ONp, 1-aminoadamantane, aminomethylcyclohexane, indoline, phenylethylamide, or dicyclohexylamide.
    • 本发明的特征在于新颖的肽衍生物,称为Reversins,并且它们用于降低多药物转运蛋白MDR1活性的方法,以克服哺乳动物的多药耐药性。 肽衍生物具有式(I)X1n-X2-X3(X4)n-X5,其中n为0或1,并且各个n相同或不同; X1是BOC,BOC-Asu,Z-Asu,苄氧基羰基,Glu(OBzl)-OBz1,Trp-OMe,Trp-Phe-OMe,Phe-Trp-OMe,Phe-Phe-OtBu,Trp-Trp-OtBu,吲哚乙酰 ,苯甲酰基,1-4个碳的烷基烷基,二苄酰胺,胰蛋白酶,1-氨基 - 金刚烷,氨基甲基环己烷,二氢吲哚,苯乙酰胺或二环己基酰胺; X2是Glu(OBzl),Asp(OBzl),琥珀酰基,O,O-二苯甲酰基联苯酰基,二苯甲酰基,粘蛋白,Thx,Cpa,Asu,Nal,Pen,Phg,Dbt,Lys(BOC),Lys(Z) Bzl),Thr(Bzl),Glu(OtBu),叔-Leu,Leu,Nle,Pro,Phe,Tyr(Bzl)或Ser(Bal) X3是Asp,Asu,Lys,Glu,Trp,Thx,Cpa,Nal,Pen,Phg,Dbt,Glu(OtBu),叔-Leu,Leu,Nle,Pro,Tyr,Phe或Tyr(Bzl); X4是BOC-Glu(OBzl),Glu(OBz1),Asu,OBz1,Bzl,BOC,BOC-Lys(BOC),Z-Glu(OtBu),Asp(OBzl),Asp(OBz) O-(环己基),芴基甲基酯,Glu(OtBu),Glu(OtBu)-OBzl,1-氨基 - 金刚烷,氨基甲基环己烷,二氢吲哚,苯乙基胺或二环己基酰胺; 和X5是OMe,OBz1,OtBu,Phe-OMe,-O-(环己基),Trp-OMe,(氯苯基) - 异丁基酰胺,芴甲基酯,ONp,1-氨基金刚烷,氨基甲基环己烷,二氢吲哚,苯乙酰胺或二环己基酰胺。
    • 9. 发明授权
    • Process for obtaining sexual products from mammals suitable for natural
or artificial fertilization
    • 从适合天然或人工受精的哺乳动物获得性产品的过程
    • US4753928A
    • 1988-06-28
    • US886618
    • 1986-07-18
    • Tamas GulyasCsaba BanhaziZoltan GrafAniko HorvathGyorgy KeriEszter KovatsIstvan Teplan
    • Tamas GulyasCsaba BanhaziZoltan GrafAniko HorvathGyorgy KeriEszter KovatsIstvan Teplan
    • A61K35/12A61K38/00A61K38/04A61K38/08A61K38/09A61K38/22A61P5/00A61P13/02A61P15/00C07K7/23C07K14/575A61K37/43
    • A61K38/09Y10S514/80Y10S930/13
    • The invention relates to a process for producing sexual products suitable for natural or artificial fertilization from mammalia through controlling the activity of their sexual organs in their pre- and post-natal lives, during their infancy, puberty and mature state and, in a given case, to produce offsprings from them as well as to increase several times the production of sexual products to a level far above that typical of the life's performance of the species. According to the invention the mammalia are treated at least once and at most 60 times with a compound of general formula (I),Glp-His-Trp-Ser-Tyr-X.sub.1 -X.sub.2 -X.sub.3 -Pro-X.sub.4, (I)whereinX.sub.1 means a glycil-group or any other natural or synthetic D-aminoacid group,X.sub.2 means an L-aminoacid-group with a side chain of an alkyl-, phenyl, or triptophyl group containing 1-4 carbon atoms,X.sub.3 means an L-aminoacid group having a side chain of an alkyl group with 1-4 carbon atoms or an alkanoyl-amide group of 2-4 carbon atoms andX.sub.4 means a glycil-amide or an alkylamide group of 1-4 carbon atoms,or a salt or metal complex thereof in a dose of 0.01 to 500 .mu.g/body weight kg (bwkg), preferably 1 to 100 .mu.g/bwkg, wherein intervals of at least two hours and at most 7 days, preferably 2 to 8 hours, are kept between the individual treatments.
    • 本发明涉及通过在其婴儿期,青春期和成熟状态下控制其性器官在其生前和产后生活中的活性来产生适合于哺乳动物自然或人造受精的性产品的方法,并且在给定的情况下 ,以产生他们的后代,并将性产品的数量增加到远远高于该物种的生命表现的典型水平。 根据本发明,用通式(I)的化合物,Glp-His-Trp-Ser-Tyr-X1-X2-X3-Pro-X4,(I)至少治疗一次至多60次, X1表示甘氨酰基或任何其他天然或合成的D-氨基酸基团,X2表示具有1-4个碳原子的烷基 - ,苯基或triptophyl基团侧链的L-氨基酸,X3表示L 具有1-4个碳原子的烷基或2-4个碳原子的烷酰基 - 酰胺基的侧链的氨基酸组,X 4表示1个碳原子的甘氨酰胺或烷酰胺基,或盐 或其金属络合物,其剂量为0.01〜500μg/体重kg(bwkg),优选为1〜100μg/ bwkg,其中间隔至少2小时,最多7天,优选2〜8小时为 保持个人治疗之间。